ERBB2 and neoplasm: Between June 2004 and October 2006, 122 patients (64 and 58 from EGF100642 and EGF104911, respectively) were enroled; 100 had HER2-positive tumours (defined as IHC3+ or IHC2+ and FISH positive) and 22 (cohort B) had HER2-negative tumours (defined as IHC 0/1+ or FISH negative).